Overview

A Multiple Dose Study of LY3023703 in Healthy Participants

Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
This is a study of LY3023703 in healthy participants. The purposes of this study are to look at safety, how well the study drug is tolerated, how much of the study drug gets into the blood stream and how long it takes the body to remove the study drug. The effects of LY3023703 on blood pressure after 28 days of dosing will be studied. Information about any side effects that occur will be collected. The study is expected to last 21 weeks.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Celecoxib